In this context, a study appearing in Frontiers of Medicine explores the potential of dronedarone, an FDA-approved drug, in inhibiting ESCC proliferation through the CDK4/CDK6-RB1 axis ...

Dronedarone increased the risk for cardiovascular events in high-risk patients with permanent atrial fibrillation of at least 6 months' duration. In the placebo-controlled ATHENA trial ...

Amiodarone has greater efficacy than dronedarone for the maintenance of sinus rhythm in patients with atrial fibrillation (AF), whereas dronedarone has a better safety profile that could result in ...

Two identical multicenter trials were conducted to assess the efficacy of dronedarone, a potential alternative to amiodarone, for maintaining sinus rhythm in patients with atrial fibrillation (AF ...

Journal Article, January 26, 2012 Dronedarone: A Cautionary Tale From PALLAS While the anti-arrhythmic drug dronedarone proved safe and effective in patients with intermittent atrial fibrillation ...